KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Net Income towards Common Stockholders readings, the most recent being $366.0 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 71.83% to $366.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 billion, a 182.43% increase, with the full-year FY2025 number at $1.4 billion, up 171.12% from a year prior.
  • Net Income towards Common Stockholders hit $366.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $466.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $466.0 million in Q4 2025 to a low of -$2.1 billion in Q4 2022.
  • Median Net Income towards Common Stockholders over the past 5 years was -$506.0 million (2023), compared with a mean of -$533.7 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 111.53% in 2022 and later skyrocketed 265.25% in 2025.
  • Teva Pharmaceutical Industries' Net Income towards Common Stockholders stood at -$2.1 billion in 2022, then surged by 92.76% to -$154.0 million in 2023, then plummeted by 83.12% to -$282.0 million in 2024, then skyrocketed by 265.25% to $466.0 million in 2025, then fell by 21.46% to $366.0 million in 2026.
  • The last three reported values for Net Income towards Common Stockholders were $366.0 million (Q1 2026), $466.0 million (Q4 2025), and $428.0 million (Q3 2025) per Business Quant data.